Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Profit After Tax (2022 - 2025)

Summit Therapeutics' Profit After Tax history spans 4 years, with the latest figure at -$219.2 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 258.11% year-over-year to -$219.2 million; the TTM value through Dec 2025 reached -$1.1 billion, down 387.81%, while the annual FY2025 figure was -$1.1 billion, 387.81% down from the prior year.
  • Profit After Tax reached -$219.2 million in Q4 2025 per SMMT's latest filing, up from -$231.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$14.7 million in Q2 2023 to a low of -$565.7 million in Q2 2025.
  • Average Profit After Tax over 4 years is -$139.7 million, with a median of -$58.3 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: skyrocketed 91.98% in 2024, then plummeted 836.84% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$19.2 million in 2022, then plummeted by 90.17% to -$36.6 million in 2023, then plummeted by 67.37% to -$61.2 million in 2024, then crashed by 258.11% to -$219.2 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Profit After Tax are -$219.2 million (Q4 2025), -$231.8 million (Q3 2025), and -$565.7 million (Q2 2025).